Personlig profil

Kort præsentation

Experienced leader with many years of management in the cutting-edge fields of cell therapy and gene editing (viral- and non-viral). Passionate about driving innovation and transforming healthcare through groundbreaking technologies (TIL-therapy, CAR-T therapy). Proven track record of guiding cross-functional teams, fostering collaboration, and successfully navigating complex regulatory landscapes. Committed to advancing the frontiers of science and delivering life-changing treatments to patients in need.

Primære forskningsområder

With a substantial tenure in research spanning many years, my primary area of expertise focus on translational research, bridging the gap between scientific discovery and practical application. My research is primarily oriented toward adoptive cell therapy, with a particular emphasis on T cells and lineage differentiated immune cells.
In addition to advancing scientific knowledge, I am actively involved in technology transfer, facilitating the seamless transition of research findings from the laboratory bench to clinical implementation. Gene editing technology (viral and non-viral) has been a pivotal tool in my work, allowing for innovative approaches in T-cell immunotherapy and precision medicine.
Throughout my career, I have demonstrated a commitment to project development, ensuring that research efforts lead to tangible benefits for patients. My dedication to the bench-to-bedside journey, coupled with a keen focus on gene editing and immunotherapy, underscores my commitment to making a meaningful impact in the field of translational research.

Aktuel forskning

My current research focus is in the area of molecular and cellular tumor immunology, particularly the development of gene-engineered T cells, tailored to treat cancer:

(1) engineering of T cells with tumor-specific synthetic TCRs or chimeric antigen receptors (CARs) for adoptive immunotherapy (ACT)

(2) manipulate co-stimulatory pathways to improve expansion of tumor-resident tumor-infiltrating lymphocytes (TILs) enriched for tumor specificity

(3) genome editing using CRISPR/Cas9 to target cell-intrinsic pathways that restrict T-cell effector functions and their anti-tumor potential

(4) Development of isolation and expansion methods for TIL therapy and to produce large-scale GMP-grade TIL products for ACT clinical trials of melanoma and other solid tumors


Dyk ned i forskningsemnerne, hvor Özcan Met er aktive. Disse emneetiketter kommer fra denne persons arbejder. Sammen danner de et unikt fingerprint.
  • 1 Lignende profiler

Samarbejde og topforskningsområder i de sidste fem år

Seneste eksterne samarbejde på lande-/områdeniveau. Dyk ned i detaljerne ved at klikke på prikkerne eller